Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate

Laurus Labs Limited🇺🇸 United States

FDA Page

Effective Date: Nov 15, 2023
Approval ID: 1f8f9fe1-b8fd-4f65-8832-9d3d6802d076
Products: 1 registered
Version: 2

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use Initial U.S. Approval: 2018

Quick Stats

Total Products1

Labelers2

Label Sections19

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.